Noticias y Actividades de Avenzo Therapeutics
Presencia
Sede: Estados Unidos
Fusión, adquisición y financiación con participación de Avenzo Therapeutics.
- Rallybio and Avenzo Therapeutics have announced they will merge (publicado el 1 de junio de 2026)..
Ejecutivos
Ver el organigrama con sus 33 ejecutivos principales
Biografías más buscadas en Avenzo Therapeutics
- Athena Countouriotis, Co-Founder, Chief Executive Officer and Chai...
- Simeon George, Director
- Garry Nicholson, Independent Director
Recientes movimientos de ejecutivos en Avenzo Therapeutics
- Sherry Wunder que ha sido Director, Clinical Data Management, ha ascendido a Senior Director, Clinical Data Management (noticia publicada el 31 de marzo de 2026).
- Heather Sun que ha sido Director, Business Development, ha ascendido a Senior Director, Business Development (noticia publicada el 31 de marzo de 2026).
- Robyn Gavin que ha sido Associate Director, Medical Writing, ha ascendido a Director, Medical Writing (noticia publicada el 31 de marzo de 2026).
Haga clic aquí para ver otros movimientos en Avenzo Therapeutics
Crear su alerta
para seguir los movimientos de los ejecutivos en Avenzo Therapeutics.
Biotecnología
Avenzo Therapeutics tiene 2.405 competidores entre los que se incluyen Eurofins (Luxemburgo), Lonza (Suiza) y BioNTech (Alemania).
Popular M&A news in Biotecnología
- IMU Biosciences acaba de anunciar una recaudación de fondos de 53 millones de dólares. (publicado el 3 de junio de 2026).
- NewLimit acaba de anunciar una recaudación de fondos de 435 millones de dólares. (publicado el 3 de junio de 2026).
- Rallybio and Avenzo Therapeutics have announced they will merge (publicado el 1 de junio de 2026)..
Otros contactos sugeridos en el sector Biotecnología
Noticias
Últimos comunicados de prensa de Avenzo Therapeutics
- Avenzo Therapeutics Announces First Patient Dosed in Combination Cohort Evaluating CDK4 Selective Inhibitor (AVZO-023) with CDK2 Selective Inhibitor (AVZO-021) In Ongoing Phase 1/2 ORION-1 Study | Avenzo Therapeutics
- Avenzo Therapeutics to Present Updated Results from the Phase 1 Study of AVZO-021, a Potential Best-in-Class CDK2 Inhibitor, at the 2026 American Society of Clinical Oncology Annual Meeting | Avenzo Therapeutics
- Avenzo Therapeutics Presents Initial Results from the Phase 1/2 Study of AVZO-021, a Potential Best-in-Class CDK2 Inhibitor, at the 2025 San Antonio Breast Cancer Symposium | Avenzo Therapeutics
- Avenzo Therapeutics Granted Fast Track Designation for AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate, for the Treatment of Patients with Urothelial Cancer Previously Treated with Enfortumab Vedotin | Avenzo Therapeut
- Avenzo Therapeutics Announces Appointment of Scott Lipman as Chief Financial Officer | Avenzo Therapeutics
- Avenzo Therapeutics Granted Fast Track Designation for AVZO-1418, a Potential Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate, for the Treatment of Patients with EGFR-Mutated TKI-Pretreated NSCLC | Avenzo Therapeutics
- Avenzo Therapeutics to Present Initial Results from the Phase 1 Study of AVZO-021, a Potential Best-in-Class CDK2 Inhibitor, at the 2025 San Antonio Breast Cancer Symposium | Avenzo Therapeutics
- Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate | Avenzo Therapeutics
- Avenzo Therapeutics Announces $60 Million Series B Financing | Avenzo Therapeutics
- Avenzo Therapeutics Announces FDA Clearance of Investigational New Drug Application for AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate | Avenzo Therapeutics
- View more press releases Close
Redes sociales sobre Avenzo Therapeutics
- Avenzo Therapeutics en Wikipedia, Google News y Yahoo Finance
- Avenzo Therapeutics en LinkedIn, Twitter y YouTube
